Bino Pathiparampil of IIFL says he does not see a secular upside in Ranbaxy Labs even at these levels. According to him, the stock continues to be expensive even after the underperformance.
first published: Apr 18, 2013 04:52 pm
A collection of the most-viewed Moneycontrol videos.
Why markets haven’t delivered and why they will turn now
Nifty Upmove Hinges On Quarterly Earnings; Will LG Electronics See A Listing Pop?|Opening Bell Live
Live: Nifty snaps 2-day winning streak but rebounds from day's low | Closing Bell | 4K
Sridhar Vembu on Zoho, Arattai. Swadeshi Tech, AI, and India’s Digital Future | Exclusive Interview
